

INFORME DE BÚSQUEDA DE PATENTES

N° de solicitud: NC2016/0005576

CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)

PALABRAS CLAVE UTILIZADAS "Disulphide-stabilised variable fragment" or "dsFv", tribody

CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA CIP: C07K 16/46

DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)

Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/ Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI	NA			
ISA/IPEA (EPO)	Mertens et al. 2004	01/02/2004	1 - 18	X
EPO	WO2013163427	31/10/2013	1 -18	Y
EPODOC	na			

*** Categorías especiales de documentos citados:

“A” documento que define el estado general de la técnica no considerado como particularmente relevante.

“E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior.

“P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.

“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado.

“Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.

**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.

Literatura no patente

**Se incluye entre otros, toda la referencia de la literatura no patente.

Mertens et al: "New Strategies In Polypeptide And Antibody Synthesis: An Overview", Cancer Biotherapy And Radiopharmaceuticals, vol. 19, no. 1, 1 February 2004 (2004-02-01), pages 99 - 109

Fecha del reporte de búsqueda:

07/03/2018

[SS 9] DSFV

Results in EPODOC 34

[SS 10] 9 AND TRIBODY

Results in EPODOC 0

[SS 11] 9 AND MULTISPECIFIC

Results in EPODOC 0

[SS 12] 9 AND ANTIBODY

Results in EPODOC 22

[SS 13] 9 AND DISULFIDE

Results in EPODOC 7

[SS 14] 13 AND PD<20140625

Results in EPODOC 3


2/3 © EPODOC / EPO

PN - [W003104432](#) A2 20031218

PD - 2003-12-18

TI - (A2 A3)
ANTI-CD30 STALK AND ANTI-CD30 ANTIBODIES SUITABLE FOR USE IN IMMUNOTOXINS

AB - (A2 A3)
CD30 is a receptor expressed on cells of Hodgkin's disease and certain leukemias. The extracellular portion of CD30 is cleaved, releasing a form known as sCD30. The invention relates in part to the discovery that a residual, extracellular "stalk" of CD30 remains after cleavage of sCD30. The stalk provides an advantageous and previously unrecognized target for immunotoxins. The invention provides antibodies that bind to the CD30 stalk or to epitopes destroyed upon the cleavage of CD30 which results in the stalk. The invention further provides new anti-CD30 antibodies that form effective immunotoxins and are particularly suitable for making **disulfide** stabilized Fv ("dsFv")-immunoconjugates. The **dsFv** immunoconjugates can be used as reagents to label CD30-expressing cancer cells or to inhibit the growth of CD30-expressing cancer cells. Moreover, the invention provides anti-CD30 antibodies that activate complement-dependent cytotoxicity.



3/3 © EPODOC / EPO

PN - [RU2003123100](#) A 20050310

PD - 2005-03-10

TI - (C2)
SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY

AB - (C2)
FIELD: medicine, oncology, genetic engineering, pharmacy. ^ SUBSTANCE: invention relates to a peptide or polypeptide representing a Fv-molecule, its genetic engineering construction, fragment of Fv-molecule or its genetic engineering construction able to bind leucosis cells and cells expressing glycolipid. The selective and/or specific binding with target-cell is determined firstly by the first hypervariable site being Fv-molecule is a single-chain Fv-molecule or **disulfide** Fv-molecule (scFv or **dsFv**) and can be labeled by one or more labels. Fv molecule comprises variable sites of heavy and light chain wherein variable site of heavy chain comprises CDR3, CDR2 and CDR1 sites with amino acids sequences given in the invention description. Invention provides using peptides or polypeptides for design of an antitumor pharmaceutical compositions based on the specific direction for enhanced binding on essentially exposed and/or superexpressed binding site in target-cell or inside of its. Also, binding with a target-cell is carried out for benefit of other cells on which or inside of these cells this binding site is not essentially available and/or expressed. ^ EFFECT: valuable biological and medicinal properties of antibodies. ^ 11 cl, 25 dwg, 11 tbl, 10 ex